Search company, investor...

Predict your next investment

Non-Profit Foundation
FINANCE | Investment Firms & Funds
chanzuckerberg.com

Investments

60

Portfolio Exits

7

Partners & Customers

10

Service Providers

1

About Chan Zuckerberg Initiative

The Chan Zuckerberg Initiative was launched by Facebook founder and CEO Mark Zuckerberg and Dr. Priscilla Chan, a paediatrician and founder of the Primary School. It focuses to help small companies to grow by supporting them through funding. It is based in Redwood City, California.

Headquarters Location

Redwood City, California, 94063,

United States

Are you an investor?
Submit your portfolio details now to be considered in our investor rankings.

Expert Collections containing Chan Zuckerberg Initiative

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Chan Zuckerberg Initiative in 1 Expert Collection, including Education Technology (Edtech).

E

Education Technology (Edtech)

58 items

Latest Chan Zuckerberg Initiative News

DZNE neuroscientist receives grant to study link between neurodegenerative diseases and mental health

Nov 11, 2023

Neurodegenerative diseases like Alzheimer's and Parkinson's can be associated to depression and anxiety. Dr. Sabine Krabbe, a neuroscientist at DZNE's Bonn site, is receiving 1.2 million US dollars from the Chan Zuckerberg Initiative to understand the mechanisms involved in the onset of these syndromes. To this end, she aims to examine the function of the brain's "emotion center" using new methodologies to examine the function of single cells in experimental mouse models. The study will run for four years and intends to pave the way for better treatments in humans affected by these conditions. Psychiatric disorders are shared by multiple neurogenerative diseases, affecting around 60 to 70 percent of patients. Anxiety and depression are particularly common. These issues affect the patients' well-being and severely reduce their quality of life. Remarkably, they can occur years before the onset of memory problems or movement disturbances. In other words, long before Alzheimer's, Parkinson's or another neurogenerative disease is diagnosed. This indicates that there must be early biological causes in addition to the mental burden later caused by diagnosis." Dr. Sabine Krabbe, neuroscientist at DZNE's Bonn site With the funded project, the neuroscientist, who heads a research group at DZNE's Bonn site, aims to contribute to a better understanding of the underlying phenomena. She says: "I not only want to understand the neuronal processes, but also find approaches so that psychiatric disorders associated with neurodegenerative diseases can be treated better." Spotlight on the emotion center At a microscopic level, diseases such as Alzheimer's and Parkinson's have especially one thing in common that might be related to psychiatric problems: protein deposits in the amygdala, the brain region that is particularly involved in controlling emotions. Hence it is sometimes called the brain's "emotion center". "My assumption is that these proteins disrupt the neuronal networks within the amygdala and that this causes the psychiatric phenotypes. In this respect, my research focuses on the amygdala and specifically on psychiatric symptoms in neurodegeneration. We want to find out how these abnormal proteins affect the amygdala. To date, their influence has mainly been investigated in other brain areas." Behavioral experiments The research project is scheduled to run for four years and is extremely complex, as it combines extensive behavioral experiments with sophisticated microscopy methods. The focus of the studies will be on mice with protein deposits in the amygdala similar to those occuring in Alzheimer's or Parkinson's disease. In technical jargon, these are referred to as "mouse models". "The amygdala has a similar structure and function in all mammals. We can therefore learn a lot about processes in the human brain from observing mice," says Krabbe. "For example, we will analyse how mice explore an unknown environment and whether the animals are courageous or rather reserved. From this, we can draw conclusions about their emotional state. We will use a whole range of standardized test protocols for these and similar experiments. And we can do this through different phases of disease to observe changes associated with its progression." Cellular precision The behavioral experiments are complemented by microscopic measurements of the activity of neural networks and even individual cells. For this, Krabbe and her team are using miniature microscopes weighing less than two grams. "A mouse can wear such a device on its head without any problems, while it moves around freely. We record what the animal is doing at a particular time and what is happening simultaneously in the amygdala. Behavior can thereby be linked to neuronal activity, and changes over the progression of the disease can be registered," explains Krabbe. "Furthermore, we have techniques to identify different cell types in the amygdala. This allows us to determine, for example, whether the disease affects some types of neurons more than others." Searching for common mechanisms The Bonn scientist presumes that different neurodegenerative diseases influence the amygdala in a similar way. "This would explain why similar psychiatric symptoms are observed in disorders as different as Alzheimer's and Parkinson's. In light of this, we are investigating corresponding mouse models," says Krabbe. "I therefore hope to find common mechanisms in the pathology within the amygdala. This would probably enable a joint therapeutic approach. Many people with neurodegeneration could benefit from this." International network The selection by the Chan Zuckerberg Initiative also offers Sabine Krabbe the opportunity to interact with numerous experts. This is an appealing prospect for the 39 year-old neuroscientist: "Together with my team, I am part of an international community, the Neurodegeneration Challenge Network that includes individuals from diverse disciplines and expertise. It consists of both junior researchers new to the field and established scientists who have been working on neurodegeneration for a long time. You can pick up a lot of tips and advice from such a community. On the other hand, I am looking forward to contributing my experience with our very specific methodology and the experimental data we will generate." Source:

Chan Zuckerberg Initiative Investments

60 Investments

Chan Zuckerberg Initiative has made 60 investments. Their latest investment was in Undiagnosed Diseases Network Foundation as part of their Grant on September 9, 2023.

CBI Logo

Chan Zuckerberg Initiative Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

9/14/2023

Grant

Undiagnosed Diseases Network Foundation

$2.5M

Yes

2

2/27/2023

Grant

Lieber Institute for Brain Development

$1M

Yes

1

12/13/2022

Grant

Solve M.E.

$0.25M

Yes

1

12/12/2022

Grant - II

Subscribe to see more

$99M

Subscribe to see more

10

12/8/2022

Series D - II

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/14/2023

2/27/2023

12/13/2022

12/12/2022

12/8/2022

Round

Grant

Grant

Grant

Grant - II

Series D - II

Company

Undiagnosed Diseases Network Foundation

Lieber Institute for Brain Development

Solve M.E.

Subscribe to see more

Subscribe to see more

Amount

$2.5M

$1M

$0.25M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

1

1

10

10

Chan Zuckerberg Initiative Portfolio Exits

7 Portfolio Exits

Chan Zuckerberg Initiative has 7 portfolio exits. Their latest portfolio exit was Sawyer on November 06, 2023.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

11/6/2023

Acquired

$99M

2

9/21/2021

Reverse Merger

Subscribe to see more

$99M

Subscribe to see more

10

8/3/2021

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

10/5/2020

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

7/2/2020

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

11/6/2023

9/21/2021

8/3/2021

10/5/2020

7/2/2020

Exit

Acquired

Reverse Merger

Acquired

Acquired

Acquired

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

2

10

10

10

10

Chan Zuckerberg Initiative Acquisitions

1 Acquisition

Chan Zuckerberg Initiative acquired 1 company. Their latest acquisition was Meta on January 23, 2017.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

1/23/2017

Series A

$99M

$9.65M

Acquired

4

Date

1/23/2017

Investment Stage

Series A

Companies

Valuation

$99M

Total Funding

$9.65M

Note

Acquired

Sources

4

Chan Zuckerberg Initiative Partners & Customers

10 Partners and customers

Chan Zuckerberg Initiative has 10 strategic partners and customers. Chan Zuckerberg Initiative recently partnered with Harvard University on September 9, 2022.

Date

Type

Business Partner

Country

News Snippet

Sources

9/23/2022

Partner

United States

1

9/19/2022

Partner

United States

1

2/2/2022

Vendor

United States

Komodo healthcare partners with Mark Zuckerberg's philanthropic effort

Komodo healthcare , a data analytics and software company , has entered a partnership with the Chan Zuckerberg Institute , giving rare disease advocacy groups within the institute access to Komodo 's software .

1

1/26/2022

Partner

United States

Subscribe to see more

Subscribe to see more

10

8/1/2021

Partner

United States

Subscribe to see more

Subscribe to see more

10

Date

9/23/2022

9/19/2022

2/2/2022

1/26/2022

8/1/2021

Type

Partner

Partner

Vendor

Partner

Partner

Business Partner

Country

United States

United States

United States

United States

United States

News Snippet

Komodo healthcare partners with Mark Zuckerberg's philanthropic effort

Komodo healthcare , a data analytics and software company , has entered a partnership with the Chan Zuckerberg Institute , giving rare disease advocacy groups within the institute access to Komodo 's software .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

1

1

10

10

Chan Zuckerberg Initiative Service Providers

1 Service Provider

Chan Zuckerberg Initiative has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Counsel

General Counsel

Service Provider

Associated Rounds

Provider Type

Counsel

Service Type

General Counsel

Partnership data by VentureSource

Chan Zuckerberg Initiative Team

4 Team Members

Chan Zuckerberg Initiative has 4 team members, including current Founder, Chief Executive Officer, Mark Elliot Zuckerberg.

Name

Work History

Title

Status

Mark Elliot Zuckerberg

Founder, Chief Executive Officer

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Mark Elliot Zuckerberg

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Title

Founder, Chief Executive Officer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.